Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Study of Gene-activated Bone Substitute Based on Octacalcium Phosphate and Plasmid DNA Encoding VEGFA Gene and Xenogenic Bone Matrix for Alveolar Ridge Augmentation: an Open-label Randomized Controlled Trial

NCT04511689 is registered in ClinicalTrials.gov with Histograft Co., Ltd. as lead sponsor.

NCT NCT04511689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04511689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Study of Gene-activated Bone Substitute Based on Octacalcium Phosphate and Plasmid DNA Encoding VEGFA Gene and Xenogenic Bone Matrix for Alveolar Ridge Augmentation: an Open-label Randomized Controlled Trial
Lead sponsor
Histograft Co., Ltd.
Phase
Observational
Overall status
Unknown status
Start date
July 1, 2020
Completion date
August 1, 2021
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alveolar bone loss, alveolar ridge pathology | gingiva | dental